European Parliament greenlights Horizon Europe priorities
As a first result of the trilogue on the 100m+ Horizon Europe programme, MEPs backed the backbone of the EU’s future research and innovation programme.
Biotechpharma UAB expanding production
Lituanian CDMO Biotechpharma UAB has invested 50m in order to expand its production capacity to 5000 litres.
Kiadis Pharma NV to acquire CytoSen Therapeutics, Inc.
Kiadis Pharma NV has entered a definitive agreement to acquire US-based CytoSen Therapeutics, Inc. in order to create a leader in cell-based cancer immunotherapy.
Treating diabetes by mimicking gut bacteria effects
Researchers at University of Glasgow report that modulation of a specific GPCR results in health benefits normally mediated by a healthy gut microbiome.
Immunic lists at Nasdaq
Chronic inflammatory disease company Immunic Therapeutics starts Nasdaq-trade following merger with Vital Therapies.
Preventing virus infections in newborns
Scientists from Belgium and the US have found a way to prevent the devasting consequences of herpes infections for newborn babies.
Evotec and Indivumed join forces in CRC
Evotec SE and Indivumed GmbH have entered into a drug R&D collaboration aimed at developing first-in-class colorectal cancer treatments.
Theranexus colloborates with AI expert Dyliss
Lyon-based neurology specialist Theranexus SA has launched a new bioinformatics partnership with systems biology data analysts from Dyliss (Dynamics, Logics and Inference for biological Systems and Sequences).
uniQure Receives FDA Fast Track Designation for AMT-130
Following the FDA granted AMT-130 fast track designation, uniQure NV announced it will start Phase I/II testing of the Huntingtons Disease gene therapy in Q2/2019.
Sanofi ends option phase of rare disease partnership with Alnylam
Sanofi and Alnylam have agreed to end the research and option phase of the companies’ RNAi therapeutics alliance in rare genetic diseases.